Conolidine’s analgesic effects stem from its conversation with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors from the central nervous method, conolidine modulates alternate molecular targets. A Science Advances study uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://danielg663tzh0.get-blogging.com/profile